Multi-site phase 3 adaptive trial of psilocybin
Latest Information Update: 20 Oct 2021
At a glance
- Drugs Psilocybin (Primary)
- Indications Major depressive disorder
- Focus Registrational; Therapeutic Use
- 20 Oct 2021 New trial record
- 13 Oct 2021 According to a MYND Life Sciences media release, this trial will be initiated within 12 months completion of phase 2 trial and this trial will form the basis for regulatory approval by the Therapeutic Goods Association ("TGA").